Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

Despite the unfavorable trial results, iTeos Therapeutics has initiated a strategic review to maximize shareholder value. The company’s CEO, Michel Detheux, Ph.D., expressed disappointment over the ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...